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Abstract 
The co-processing of active pharmaceutical ingredient (API) with an excipient which has a high 
glass transition temperature (Tg) is a recognised strategy to stabilise the amorphous form of a 
drug.  This work investigates whether co-processing a model API, sulfadimidine (SDM) with a 
series of low Tg excipients prevents or reduces amorphisation of the crystalline drug.  It was 
hypothesised that these excipients could exert a Tg lowering effect, resulting in composite Tg 
values lower than that of the API alone and promote crystallisation of the drug.  Milled SDM and 
co-milled SDM with glutaric acid (GA), adipic acid (AA), succinic acid (SA) and malic acid 
(MA) were characterised with respect to their thermal, X-Ray diffraction, spectroscopic and 
vapour sorption properties. 
SDM was predominantly amorphous when milled alone, with an amorphous content of 82 %.  
No amorphous content was detected by dynamic vapour sorption (DVS) on co-milling SDM 
with 50 % w/w GA, and amorphous content of the API was reduced by almost 30 %, relative to 
the API milled alone, on co-milling with 50 % w/w AA.  In contrast, amorphisation of SDM was 
promoted on co-milling with 50 % w/w SA and MA, as indicated by near infrared (NIR) 
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spectroscopy.  Results indicated that the API was completely amorphised in the SDM:MA co-
milled composite. 
The saturated solubility of GA and AA in the amorphous API was estimated by thermal methods.  
It was observed that the Tg of the co-melt quenched composites reached a minimum and levelled 
out at this solubility concentration.  Maximum crystallinity of API on co-milling was reached at 
excipient concentrations comparable to the saturated concentration solubility of excipient in the 
API.  Moreover, the closer the Hildebrand solubility parameter of the excipient to the API, the 
greater was the inhibition of API amorphisation on co-milling.    
The results reported here indicate that an excipient with a low Tg coupled with high solubility in 
the API can prevent or reduce the generation of an amorphous phase on co-milling. 
Keywords: glass transition, amorphous, co-milling, solubility, excipient, thermal methods, 
vapour sorption, X- Ray diffraction 
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1. Introduction  
During pharmaceutical manufacturing, the active pharmaceutical ingredient (API) particle size is 
rarely optimal, or even within the desired size range, following crystallisation and isolation.1 
Therefore the material is often subjected to size reduction techniques such as milling, which 
additionally carries the possibility of altering the solid state form of the material.  This can lead 
to the generation of a metastable polymorph, to increased disorder within a crystalline material 
or to a disordered amorphous state.2-4 The latter two consequences are often undesirable and 
unintentional as these high energy forms will tend to revert back over time to the more 
energetically favoured crystalline state, with subsequent implications for processability, stability 
and performance.5,6 
The position of the glass transition temperature (Tg) of a material relative to the milling 
temperature has a direct influence on whether polymorphic transformation or amorphisation is 
observed upon milling.7 It has been observed that milling a material below its Tg favours 
amorphisation. Several APIs including salbutamol sulphate8, cimetidine9 and griseofulvin10 were 
amorphised upon milling.  In contrast, milling at elevated temperatures above the Tg value for 
mannitol11, sorbitol11 and indomethacin12 resulted in crystalline products but of a different 
polymorph.   
The amorphous form of APIs has been successfully stabilised in many cases by co-processing 
them with high Tg excipients.13-17 As the Tg is a key parameter concerning the physical stability 
of amorphous APIs, the two logical methods to ensure stability are to a) store the amorphous 
material at temperatures well below the Tg where molecular mobility is less (e.g. Tg – 50 
degrees18) or b) manipulate the dispersion Tg so that it is well above that of the storage 
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temperature.  The former is not very practical and some materials are known to crystallise at 
temperatures well below Tg.19 The latter is viable by co-processing the API with high Tg 
excipients to produce miscible molecular systems that exhibit higher composite Tg values 
relative to the amorphous API alone.20,21  In addition, specific interactions can occur between 
drug and carrier which have been shown to immobilise drug and reduce the tendency for 
crystallisation.22 
In contrast very little work has focused on trying to prevent or reduce the amorphisation of an 
API by co-processing with excipients.  Balani et al reported that amorphisation of salbutamol 
sulphate was mitigated on co-milling with a number of crystalline excipients.23 They postulated 
such effects to be due to the presence of crystalline excipient acting as nucleating seeds, aided by 
an elevated temperature above the Tg of the API during the milling operation.   
We hypothesise that the reduced Tg principle could be exploited to promote the crystallisation of 
a drug which becomes amorphous on milling.  This is conceptually possible by co-milling with a 
low Tg excipient, resulting in a system with a composite Tg lower than that of the Tg of the API 
alone.  For the excipient to exert a plasticising effect, there is an inherent assumption that both 
API and excipient must mix at the molecular level. 24   
The aims of this work were to characterise and quantify the effects of milling on the crystallinity 
of a model API and to subsequently evaluate the capability of a series of low Tg, dicarboxylic 
acids to minimise the amorphisation of the API on co-milling.  The API selected was 
sulfadimidine which has a Tg of 78 °C and is known to amorphise upon milling at room 
temperature.25 The quantification of amorphous character in partially crystalline milled powders 
is difficult.26 Here we have used several complementary techniques for the API milled alone 
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based on thermal, diffraction, spectroscopic and vapour sorption techniques.  The excipients 
chosen were glutaric acid, adipic acid, succinic acid and malic acid.  Amorphous content 
quantification following co-milling was carried out by DVS and NIR owing to ease of analysis 
and their known abilities to quantify very low levels of amorphous content.27   
 
2. Materials and Methods 
2.1. Materials.  Sulfadimidine (SDM) (molar weight (Mw) = 278.33g.mol-1), ≥ 99 % 
purity, adipic acid (AA) (Mw = 146.14 g.mol-1) 99 % purity, glutaric acid (GA) (Mw = 132.11 
g.mol-1) 99 % purity, and succinic acid (SA) (Mw = 118.09 g.mol-1), > 99 % purity were 
purchased from Sigma-Aldrich, Ireland.  Malic acid (MA) (Mw = 134.09 g.mol-1) ≥ 99 % purity 
was purchased from Fluka Chemika, Switzerland.  Solvents used in the spray drying process 
were ethanol 99.5 % v/v (Cooley Distillery, Ireland) and deionized water, prepared using a 
Millipore Elix 3 RO/EDI system.  Potassium bromide (KBr) for infrared spectroscopy analysis 
was purchased from Spectrosol, Ireland, thoroughly dried before use and stored in a dessicator 
over silica gel prior to the preparation of KBr disks. 
 
2.2. Methods.   
2.2.1. Milling. Ball milling of SDM and excipients was performed with a PM 100 high 
energy planetary mill (Retsch, Germany) at room temperature.  2.5 g of material were placed in 
stainless steel milling jars of 50 cm3 volume with three stainless steel balls of diameter 20 mm, 
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corresponding to a ball to powder mass ratio of 40:1.  The speed of the solar disk was set at 400 
rpm.  Every 20 minutes of milling was followed by a pause period of 10 minutes to avoid 
overheating. 25  As previously described, total milling time was kept constant at 15 hours 
corresponding to an effective milling time of 10 hours.25  SDM was co-milled with GA at 
different weight percentages of excipient (Xexcipient)( XGA = 5, 10, 20, 30, 40, 50 %).  SDM was 
also co-milled with 20 %, 30 %, 50 %, 70 % w/w AA, 50 % w/w SA and 50 % w/w MA.  
2.2.2. Spray drying. SDM and each excipient was spray dried using the Buchi-290 Mini Spray 
Dryer as a solution of ethanol/water 7:3 v/v.  The inlet temperature was maintained at 78 °C, 
outlet temperature was between 42 – 49 °C and a feed concentration of 0.4 % w/v was used.  
Spray drying was performed in the open mode configuration using compressed air as the drying 
medium with a pump rate of 30 %, aspirator setting of 100 % and air flow of 40 mm. 
2.2.3. Powder X-ray diffraction. Powder X-ray diffraction (pXRD) measurements were 
performed on samples placed on a low background silicon sample holder using a Rigaku 
Miniflex II desktop X-ray diffractometer (Rigaku, Tokyo, Japan).25 The pXRD patterns were 
recorded from 5 ° to 40 ° on the 2θ scale at a step of 0.05 ° s-1.  The X-ray tube composed of Cu 
anode (λCUKα = 1.54 Å), was operated under a voltage of 30 kV and current of 15 mA. 
2.2.4. Thermal analysis. Differential scanning calorimetry (DSC) experiments were conducted 
using a Mettler Toledo 821e with a refrigerated cooling system (LabPlant RP-100).  Nitrogen 
was used as the purge gas.  Hermetically sealed 40 µl aluminium pans with three vent holes were 
used throughout the study, and sample weights varied between 5 and 10 mg.  The system was 
calibrated for temperature and cell constant using indium and zinc.  A heating rate of 10 °C min-1 
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was implemented in all DSC measurements.  Analysis was carried out and monitored by Mettler 
Toledo STARe software (version 6.10) with a Windows NT operating system. 
Measurements of the heat capacity of amorphous and crystalline SDM were obtained using a 
modulated temperature DSC (MTDSC).  Experiments were conducted on a DSC Q200 (TA 
Instruments, United Kingdom) in hermetic pans with 1 pinhole and sample weights were 
between 2 and 6 mg.  The instrument was calibrated for temperature and cell constant using high 
purity indium.  Heat capacity readings were calibrated using sapphire.  The method selected was 
similar to that previously reported.25 The parameters used were as follows: heating rate, 1 °C 
min-1; amplitude of modulation, 1 °C; period of modulation, 120 s.  
High performance DSC (HyperDSC) experiments were performed with a Perkin Elmer Diamond 
DSC Pyris1 with HyperScanTM.  Helium flow was set at 60 ml. min-1 and the heating rate 
employed was 300 °C min-1.  Sample weights between 2 and 6 mg were placed in aluminium 
pans with three vent holes.  The instrument was calibrated for temperature using highly pure 
indium.   
2.2.5. Solubility determination by thermal analysis The solubility of GA and AA in SDM were 
estimated by thermal analysis. Firstly, API/excipient mixtures containing 40, 50, 60, 70, and 80 
% w/w of crystalline excipient were milled using the same milling conditions as described 
above. The resulting powders were then melted on a heating plate at 200 °C under nitrogen 
atmosphere in order to prevent chemical degradation, subsequently quenched to 25 °C and kept 
at this temperature for 2 days.  At this stage a mixture of crystalline excipient and amorphous 
API saturated with excipient was obtained, which was confirmed by pXRD. The melting 
enthalpy of the resulting crystalline phase was then determined by DSC to 130 °C for SDM:GA 
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and 180 °C for SDM:AA and plotted as a function of excipient mass fraction. A high heating rate 
(20 °C min-1) was used in order to prevent the recrystallisation of the API and gradual 
dissolution of the crystalline excipient in the amorphous API upon heating. All experiments were 
performed at least in duplicate. 
2.2.6. Fourier Transform Infrared Spectroscopy (FTIR).  Infrared spectra were recorded on a 
Nicolet Magna IT 560 ESP spectrophotometer equipped with MCT/A detector, working under 
Omnic software version 4.1.  A spectral range of 650 – 4000 cm-1, resolution 2 cm-1 and 
accumulation of 64 scans were used in order to obtain good quality spectra.  A potassium 
bromide disk method was used with 1 % (w/w) sample loading, as described previously. 25 Disks 
were prepared by compression under 8 tons for 2 minutes.   
2.2.7. Near infrared spectroscopy (NIR).  NIR spectra were collected in glass vials 
(15mm×45mm) on a PerkinElmer Spectrum One fitted with an NIR reflectance attachment.  The 
method was similar to that previously described.28 Spectra were collected with interleaved scans 
in the 10,000–4000cm−1 range with a resolution of 8 cm−1, using 32 coadded scans.  Sample vials 
were shaken and repositioned between triplicate measurements of each sample. 
NIR data analysis was carried out using the Unscrambler v.9.8 software (Camo, Norway). Pre-
processing methods, standard normal variate (SNV) transformation and second derivative 
calculations (a window size of 21 points and second order polynomial) were used separately or 
combined.  Partial least squares (PLS) regression was used to create calibration models for 
quantitative analysis, and its performance was evaluated using the correlation coefficient (R2) 
and the root mean square error (RMSE).  RMSE is termed as the root mean square error of 
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calibration (RMSEC) for the calibration set, and that of prediction (RMSEP) for the prediction 
set. 
2.2.8. Dynamic vapour sorption (DVS).  Sorption isotherms and kinetic profiles of the 
unprocessed, spray dried, milled and co-milled systems were obtained using DVS (Advantage, 
Surface Measurement Systems, Alperton, UK).  The temperature was 25.0 ± 0.1 °C and ethanol 
was used as the probe vapour.  Samples were dried at 0 % P/P0 for several hours and then 
subjected to step changes of 10 % P/P0 up to either 50 %, 70 % or 90 % P/P0, and the reverse for 
desorption.  Second sorption cycle isotherms were also determined.  The final P/P0 value was 
system specific and was determined on the basis of when crystallisation was complete for spray 
dried, milled and co-milled SDM. Absence of a mass loss in the second sorption cycle indicated 
full crystallisation.  As previously described, the sample mass was allowed to reach equilibrium 
defined as dm/dt ≤ 0.002 mg/min over 10 min, before the P/P0 was changed.
29 Sample weights 
were between 8 – 15 mg.  All DVS experiments were performed at least in duplicate and 
quantification results are expressed as averages ± standard deviation. 
2.2.9. Melt quench.  The glass transition temperature of malic acid was determined by melting 
the material in a DSC by heating to 146 °C at 10 °C min-1  and rapidly immersing the molten 
material in liquid nitrogen.  The material was then reheated from -30 – 170 °C at the same 
heating rate which allowed detection of the Tg. The glass transition temperatures of SDM:GA 
and SDM:AA composites were determined by melting the milled powders on a heating plate at 
200 °C under nitrogen atmosphere in order to prevent chemical degradation and subsequently 
quenching to 25 °C. The material was then analysed by DSC from 0 to 130 °C for SDM:GA 
composites and from 0 to 180 °C for SDM:AA composites at 20 °C min-1. 
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2.2.10. Hildebrand solubility parameter.  The Hildebrand solubility parameter was determined 
utilising the Fedors group contribution method.30 The solubility parameter for sulfadimidine as 
well as the individual excipients was calculated.   
The calculation involves the summation of molar vaporization enthalpies of structural fragments 
in the material.  The molecular volume can be derived from its density or alternatively in an 
additive fashion similar to that of the molar enthalpies.  The Hildebrand solubility parameter was 
determined from equation 1 below:    
  
  
                                  (1) 
where ∆Ev is the energy of vaporisation and Vm is the molar volume.  
 
2.2.11. Preparation of physical mixtures 
Milled SDM was mixed with milled GA and MA in a Turbula mixer (2 litre, W.A. Bachofen, 
Switzerland) at 55 rpm for 10 minutes.  The physical mixtures contained 50 % w/w excipient and 
were immediately characterised on recovery of the samples from the Turbula mixer. 
 
3. Results  
3.1. Powder X-ray diffraction and thermal analysis of unprocessed, milled and spray 
dried SDM. 
Figure 1 displays the pXRD patterns of unprocessed, milled and spray dried SDM.  Unprocessed 
SDM displayed well defined Bragg peaks, characteristic of a crystalline material.  Milled SDM 
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revealed fewer Bragg peaks which were broader and of lower intensity against a halo 
background.  Spray dried SDM was pXRD amorphous.  Spray dried SDM was used as the 
amorphous standard due to the inability to completely amorphise the API upon milling. 
Thermal analysis by HyperDSC of unprocessed SDM revealed a single endothermic peak at 198 
°C attributed to the melting of the API.  The thermograms of the milled and spray dried materials 
displayed three main features, as seen in Figure 2.   First, a step change in heat capacity was 
observed at ~ 80 °C, attributed to the glass transition temperature of SDM.  Secondly, an 
exothermic crystallisation immediately after the Tg for the milled sample and nearly 50 °C 
higher, at 130 °C, for the amorphous spray dried sample was observed.  The minor endotherm 
after the Tg for the spray dried sample could be due to enthalpic relaxation.  Milled and spray 
dried SDM melted at ~ 197 °C.  
 
3.2. Quantification of amorphous content in milled SDM. 
3.2.1. Amorphous content quantification by pXRD.    
This method is based on the principle that the integrated peak area is proportional to the degree 
of crystallinity.31,32 As pXRD measures properties specific to crystalline materials, a reduction in 
peak area with the concomitant appearance of a diffuse halo is linked to a reduction in 
crystallinity, which then can be associated with an increase in disorder or amorphousness.33 The 
crystallinity of unprocessed SDM was assumed to be 100 %.  An estimation of the degree of 
crystallinity was based on integrating the areas of Bragg peaks from the entire sample following 
milling (Ap) and comparing this to the commercial sample (Ac) (equation 2). 
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      (2) 
Table 1 displays the calculated amorphous content for milled SDM by pXRD.  
 
3.2.2. Amorphous content quantification by MTDSC 
Amorphous content quantification from DSC measurements can be performed readily by 
comparing the enthalpy of crystallisation to the enthalpy of melting.  However as these thermal 
events inevitably occur at different temperatures, it is necessary to correct for this temperature 
dependence of the enthalpy values by taking account of the heat capacity difference between the 
solid and liquid state (equation 3).34 
  
          (3) 
where ∆Hc and ∆Hm are the enthalpies of recrystallisation and melting, Tc and Tm are their 
corresponding temperatures. The term α refers to the fraction of amorphous sample which does 
not crystallise upon heating and it is obtained from the ratio of the enthalpy of melting of the 
amorphous sample to that of the crystalline sample.  Table 1 summarises the % amorphous 
content determined by MTDSC.   
 
 
Page 12 of 45
ACS Paragon Plus Environment
Molecular Pharmaceutics
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
13 
 
3.2.3. Amorphous content quantification by NIR. 
The NIR spectra (Figure 3) of the unprocessed and spray dried amorphous SDM exhibited clear 
differences in the 7000 – 6400 and 5150 – 4400 cm-1 spectral regions, with bands at 6806, 6604, 
4876, 4776 and 4490 cm-1 being specific to the crystalline form of the API.  Thus NIR was a 
suitable technique to quantify the amorphous content in milled SDM.  Amorphous /crystalline 
binary physical mixtures of SDM were prepared over the composition range of 0-100 % 
crystallinity and mixed uniformly for 3 minutes using a vortex mixer (Type 37600).  The optimal 
calibration model was obtained by using a combination of SNV and 2nd derivative pretreatments 
in the 6850 – 6400 cm-1 spectral region, which gave a good linear relationship (R2 = 0.999) 
between the calculated and the measured amorphous content with 2 PLS factors.  The RMSEC 
and RMSEP values were 0.89 % and 1.33 %.  The amorphous content value of milled SDM by 
NIR was determined to be 84 %, as documented in Table 1. 
 
3.2.4. Amorphous content quantification by DVS. 
The amorphous content was determined by a method similar to that developed by Mackin et al 
where the difference in mass uptake between the first and second sorption cycles correlates with 
amorphous content.35 As this method required a vapour induced crystallisation, and water was 
unable to induce crystallisation in the spray dried 100 % amorphous reference, ethanol was 
chosen as the probe molecule.  The milled material started to crystallise at 30 % P/P0 and thus 
the difference in mass uptake at 20 % P/P0 was used in the quantification calculations 
(highlighted in Figure 4A).   As seen in Figure 4B, a relationship between ethanol uptake before 
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and after crystallisation and % amorphous content was observed.  A linear fit of the response and 
predictor variable resulted in an R2 of 0.9949. 
 
Table 1.  Summary of amorphous content of milled SDM as quantified by pXRD, MTDSC, DVS and 
NIR. 
System % Amorphous content (±S.D) Method 
 
 
SDM milled 
88 (2) pXRD 
81 (1) MTDSC 
84 (1) NIR 
76 (3) DVS 
  
3.3. SDM co-milled with GA. 
 3.3.1. Power X- ray diffraction and thermal analysis of SDM:GA co-milled 
composites. 
Figure 5 displays the pXRD patterns arising from co-milling SDM with GA.  With XGA ≥ 10 %, 
characteristic peaks of SDM were observed with better resolution compared to when the API was 
milled alone.  Moreover the halo pattern was less pronounced, suggesting amorphisation had 
been reduced.  No shifts in peak position or new peaks were noted.   
No crystallisation exotherms were seen in the DSC thermograms following co-milling with ≥ 10 
% w/w GA (Figure 6).  An endothermic peak gradually evolved just below 80 °C due to the 
solid-solid transformation that occurs in GA.36  
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A binary eutectic system should show melt miscibility and solid immiscibility.37 The XRD 
patterns, except for the system with the lowest concentration of excipient, are representative of a 
mixture of two crystalline solids, as would be expected from a mixture which displays a eutectic 
like behaviour. The thermograms display a eutectic-like melting at 90 °C which is constant 
across all binary compositions and is at a lower temperature compared to the melting of the 
excipient (99 °C) and the drug (197 °C).  The presence of a depressed skewed melting of un-
dissolved excess API also indicates a eutectic interaction between the API and excipient.  
 
3.3.2. Quantification of amorphous content of SDM:GA co-milled 
composites. 
 3.3.2.1. Amorphous content quantification by DVS. 
The method of quantification for the co-milled composites by DVS was similar to that employed 
for the API milled alone.  The weight fraction of excipient, its behaviour in the programmed 
ethanolic environment and its overall contribution to the mass uptake was accounted for.  This is 
illustrated in equation 4 below: 23   
 
   (4) 
where ∆m is the difference in the mass uptake (%) of the API between the first and second 
sorption cycles at a system specific P/P0, ms is the sample mass in the DVS, md is the mass of the 
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API in the overall sample mass, and ∆m100 is the difference in mass uptake (%) between the first 
and second sorption cycles of the spray dried fully amorphous standard at a system specific P/P0.  
An interesting observation for the SDM:GA co-milled system was that with only 5 % w/w 
excipient, SDM started to crystallise at 20 % P/P0 (Figure 7A).  Even the minimum amount of 
GA lowered the P/P0 at which the API started to crystallise and hence the mass uptake at 10 % 
P/P0 was used for these particular composite quantification calculations.  Mass loss at higher 
P/P0 was also noted.  It should be noted that the quantification results are independent of the 
crystallisation kinetics, provided the method allows the sample to reach equilibrium at each 
partial pressure and the sample has crystallised.35 For all systems, crystallisation was complete 
before the start of the second sorption cycle.    As seen in Figure 7B, a mass loss was observed at 
50 % P/P0 for the co-milled system with XGA = 10 %, indicating some degree of amorphicity was 
still present.  No mass loss was observed for the co-milled composite with 50 % w/w GA (Figure 
7C).  
 
3.3.2.2. Amorphous content quantification by NIR. 
As mentioned in section 3.2.3., NIR spectroscopy can be used to determine amorphous content in 
multi-component physical mixtures.  Amorphous / crystalline physical mixtures of SDM were 
diluted step wise with increasing amount of milled excipient and NIR spectra collected before 
and after each step of dilution were used to build the calibration models.  From Figure 3, it can 
be seen that the spectral region of 6850 – 6400 cm-1 displayed characteristic bands for SDM, 
with no interference from GA, and thus this region was used for the PLS modelling.  The 
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amorphous content of SDM on co-milling with GA obtained from these calibration models are 
listed in Table 2. 
 
 3.4. SDM co-milled with AA, SA and MA. 
SDM was then co-milled with another 3 dicarboxylic acids; AA, SA and MA with the objective 
to see if comparable results as those observed with GA could be obtained.  Amorphous content 
was calculated by DVS and NIR as for the SDM:GA systems.  The pXRD patterns for the 
individual excipients as well as the co-milled composites with Xexcipient = 50 % are displayed in 
Figure 8.  Focusing on the Bragg peak at approximately 10 ° 2 theta indicates that, relative to the 
API milled alone, amorphisation was reduced on co-milling with AA but was promoted on co-
milling with SA and MA.    
The corresponding DVS sorption profiles for these co-milled systems are shown in Figure 9.  
The difference in mass uptake at 20 % P/P0 for the SDM:AA systems, and at 30 % P/P0 for the 
SDM:MA and SDM:SA systems was used for these DVS amorphous content calculations, in 
contrast to 10 % P/P0 which was used for the SDM:GA co-milled system.  This was because 
crystallisation occurred at higher P/P0 values for these systems. The capacity of the SDM:MA 
system to sorb ethanol increased noticeably between 20 % and 30 % P/P0 and measurements at 
10 % or 20 % P/P0 would have significantly underestimated the amorphous content for this 
system.  Amorphous content quantification by NIR was carried out similar to that described for 
SDM:GA systems and the RMSEC values for the calibration models obtained with each 
excipient were between 0.31 and 1.34. 
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Amorphous content values for all co-milled systems are displayed in Table 2.  
 
Table 2.  Summary of amorphous content of co-milled systems as quantified by DVS and NIR. 
System 
% Amorphous content (±S.D) 
DVS NIR 
SDM milled 76 (3) 84 (1) 
SDM95 : GA5 78 (2) 76 (1) 
SDM90 : GA10 30 (5) 27 (1) 
SDM70 : GA30 9 (5) 10 (1) 
SDM50 : GA50 0 (0) 4 (1) 
SDM50 : AA 50 54 (2) 52 (1) 
SDM50 : SA 50 62 (2) 96 (1) 
SDM50 : MA50 114 (5) 100 (1) 
 
3.5. Characterisation at the molecular level. 
FTIR measurements on the individual components, their physical mixtures and the 
corresponding co-milled composites were undertaken.  Particular attention was focused on the 
wavenumber regions of 3000 – 3500 cm-1 (OH and NH stretching vibrations), 1600 – 1800 cm-1 
(C=O vibration) and 1200 – 1400 cm-1 (OH bends and CH stretches) as changes in hydrogen 
bonding networks would be reflected in peak shifts in these regions.38 For this work, particular 
attention was focused was on the SDM:GA and SDM:MA systems because of the divergence in 
results obtained on co-milling with these two excipients. 
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Figure 10 displays the spectra of SDM, SDM milled, GA milled, SDM50:GA50 co-milled, 
SDM50:GA50 physical mixture, SDM50:MA50 co-milled, SDM50:MA50 physical mixture and 
milled MA.  SDM, like other related sulfa compounds has strong characteristic bands in the 
region 3390 – 3425 cm-1 due to the N-H stretching vibrations and a number of strong absorption 
bands at 1360 – 1315 cm-1 due to the asymmetric stretching vibration of the SO2 group.
38 Milling 
of the API resulted in a broadening of peaks consistent with a less ordered structure.39 The extra 
shoulder peaks at 3414 cm-1  and 3471 cm-1  are likely due to a small fraction of non hydrogen 
bonded NH which is present in the amorphous material.40 The C=O stretch at 1695 cm-1 is the 
characteristic feature of the GA spectrum and its position is very sensitive to H bonding and its 
molecular environment.  No peak shifts to either higher or lower wavenumber was observed for 
this or any of the key peaks of SDM in the spectra for either the co-milled composite or the 
physical mixture. 
 The C=O stretch in milled MA, and also in the spectra of the physical mixture, exists as an 
intense band and is split into two peaks at 1700 cm-1 and 1740 cm-1 respectively, suggesting that 
there are two populations of interactions occurring with this functional group.  The shoulder of 
the carbonyl band was no longer resolved following co-milling and a pronounced peak shift to 
1729 cm-1 was observed.  The free OH stretch in MA at 3523 cm-1 was much broader and at 
lower wavenumber for the co-milled composite compared to that present in the spectrum of the 
excipient or the physical mixture.  This, in addition to differences in the 1440-1395 cm-1 and 960 
– 880 cm-1 region where OH bends occur, could suggest interactions between the API and 
excipient.  It should be noted however that amorphous MA could not be analysed by FTIR owing 
to lack of physical stability and hence it was not possible to determine categorically whether 
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shifts in peak position were due to interactions between SDM and MA or because of a crystalline 
to amorphous transition in the excipient.   
 
4. Discussion 
In order to assess whether co-milling SDM with a number of low Tg, dicarboxylic acids could 
mitigate amorphisation in the API, it was first necessary to know how much amorphous content 
was generated when the API was milled alone.  Reasonably good agreement was obtained for all 
four characterisation methods.  Amorphous content determination was highest for pXRD.  
Milling for long periods can give rise to a true amorphous phase as well as deformed 
nanocrystallites which can be beyond the detection limit of the X-Ray.41 These nanocrystallites 
can contribute to the halo pattern and potentially bias upwards the amorphous content.  
Amorphous content by MTDSC is based on heat capacity measurements and enthalpies of 
crystallisation and melting but is not applicable to all materials, and in particular for those which 
degrade on melting.  NIR is a non invasive technique and recognised as being highly sensitive to 
small amounts of amorphous material.42   DVS is based on the different sorption capabilities of 
amorphous and crystalline materials.  This is related to the structural features of both systems, 
one being a highly organised, tightly arranged crystal lattice, the other highly disordered with a 
larger surface area and void space where moisture can accumulate.5  
The general agreement between the four methods gave a reliable indicator of the amorphous 
content in the milled API and provided a basis on which to compare the effects of co-milling 
with the selected dicarboxylic acids.   
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The dicarboxylic acids investigated are crystalline in nature and, except for malic acid, were 
resistant to amorphisation when milled, spray dried or melt quenched alone (Figure 1 and 2 in 
the Supporting Information).  Hence their theoretical Tg values were calculated using the Tg = 
Tm x 0.7 rule.43,44  Lin et al compared the values obtained by this method against those 
determined experimentally for a number of compounds and found a generally good agreement 
between the estimated and experimental values, with an average prediction error of 
approximately 5.9 %.45   The Tg values for SDM and excipients are displayed in Table 3. 
Solubility parameters are based on regular solution theory.46,47  If two components are found to 
have similar values then they would be expected to be soluble in each other.48,49   
Table 3.  Summary of solubility parameters, melting point values, Tg values, molecular weights and 
chemical structures for SDM and the dicarboxylic acids. ∆δ is the difference of the Hildebrand solubility 
parameter between API and excipient. 
System 
Hildebrand 
solubility 
parameter ‘δ’ 
(MPa
1/2
) 
∆δ 
 
Tm 
(K) 
 
Tg (K) 
Mw 
(g.mol
-1) 
Chemical structure 
Sulfadimidine 25.7 NA 470 351 
(329* ) 
278.33 
H2N
S
HN
N
N
 
Adipic acid 24.9 0.8 425 298* 146.14 
HO
O
O
OH
 
Glutaric acid 25.8 0.1 370 259* 132.11 O O
OHHO  
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Succinic Acid 27.0 1.3 460 322* 118.09 O
O
OH
HO
 
Malic acid 33.7 8.0 404  258 
(283* ) 
134.09 O
O
OH
HO
OH  
*Tg values determined by the Tg = Tm x 0.7 rule 
Quantification analysis for the composite systems was performed by DVS and NIR due to their 
enhanced sensitivity at detecting low amorphous content levels, compared to DSC and pXRD.  
Amorphous content, relative to the API milled alone, was more than halved following co-milling 
with 10 % w/w GA and completely eliminated following co-milling with 50 % w/w GA, as 
quantified by DVS.  NIR results displayed very good agreement, although 4 % amorphous 
content was still detected for the 50:50 co-milled system.  SDM has the most comparable 
solubility parameter with this excipient with a ∆δ of only 0.1 (Table 3).  GA also has a low 
calculated Tg value (-14 °C).  Although malic acid has Tg value of -15 °C, which is very similar 
to GA, co-milling SDM with this excipient completely amorphised the API, as quantified by 
both DVS and NIR.  The calculated solubility parameter indicates it has the poorest miscibility 
of all the excipients with SDM.  The amorphous content value of 114 % by DVS was due to 
complete amorphisation of the API and partial amorphisation of MA, which was confirmed by 
pXRD.  For all systems investigated, the rank order of difference of Hildebrand solubility 
parameter between API and excipient correlated with the degree of crystallinity of API on co-
milling.  Quantification results by DVS and NIR were not in agreement for the SDM:SA system.  
Based on the XRD pattern, the API was predominantly amorphous and hence the DVS result 
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would appear to have underestimated the amorphous content.  NIR was therefore considered the 
more appropriate quantification technique for this particular system.     
The difference in the FTIR spectra for the SDM:GA and SDM:MA systems could be related to 
the additional hydroxyl group on the alkyl chain of malic acid, which should provide additional 
hydrogen bonding possibilities.  It is conceivable that this networking of interactions and 
hydrogen bonding between the multiple functional groups available could immobilise the 
amorphous API and prevent its crystallisation.  Kadoya et al studied the effect of molecular 
interactions on amorphous binary solids involving amines and hydroxyl carboxylic acids and 
related this to their propensity for crystallisation.50 It was noted that the length of the diacid alkyl 
chain had limited effects on the Tg of the mixtures but that the introduction of a hydroxyl group 
had a large effect on reducing component mobility.    
The concept of transient amorphisation was not observed following intermediate analysis of the 
co-milling of SDM with GA at various time points, with both API and excipient appearing 
crystalline across all time points (3, 5, 7, 9 , 10 hours) (data not shown). The difficulty is that 
once milling is ceased, amorphisation stops and immediate crystallisation is possible prior to 
diffraction analysis. 
To further investigate if the excipients were promoting crystallisation from an amorphous state, 
milled SDM was co-milled with 50 % w/w milled GA and 50 % w/w milled MA.  The pXRD 
patterns are displayed in Figure 11 below. 
Co-milling milled SDM with 50 % w/w GA promoted crystallisation in the API, therefore 
eliminating the possibility that the excipient was physically shielding the API from the stresses 
of the milling operation.  Co-milling milled SDM with 50 % w/w MA did not cause 
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crystallisation of the API and indicates that the presence of seed crystals is not the likely 
mechanism behind the observed results.   
Due to the effectiveness of GA and AA at reducing amorphisation of SDM on co-milling, their 
respective solubilities in the API were determined by thermal analysis, as described in section 
2.2.5.  A linear relationship was observed between the composition and the enthalpy of fusion in 
both cases and the solubility of the excipient in amorphous API was estimated as the zero 
enthalpy interception point by extrapolation (Figure 12).  The presence of a single Tg value 
intermediate to that of the API and excipient was taken as an indicator of a mixed system while a 
phase separated amorphous system will display two distinct Tg values.  The melt miscibility of 
the SDM:GA and SDM:AA systems was confirmed by the presence of a single intermediate Tg 
value in the melt quenched samples.  Solubility of SA in SDM could not be determined by this 
method due to significant mass loss (chemical degradation or sublimation) upon melting.  In the 
case of MA, the excipient showed immiscibility with SDM during melt quenching experiments 
(presence of two distinct Tgs, data not shown).  These solubility results by thermal analysis were 
consistent and anticipated from the solubility parameter calculations presented in Table 3.   
Figure 13 displays a plot of experimental Tg of melt quenched samples and % crystallinity of co-
milled systems as quantified by DVS as a function of GA and AA mass fraction. 
The saturated concentrations of crystalline GA and AA in amorphous SDM were determined to 
be 34 % and 20 % respectively.  At the saturated concentration of GA and just beyond the 
saturated concentration of AA, the crystallinity of the co-milled systems approached near 
maximum and then levelled off.  Interestingly the co melt quenched systems, at their respective 
saturated concentration of excipient, had Tg minimum values of 38 °C and 42 °C respectively.  
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Nevertheless co-milling SDM with GA was more effective at mitigating amorphisation of the 
API.  This suggests that a third factor, in addition to solubility and Tg, may have a role to play in 
the observed results.  Taylor et al recently investigated the effects of polymer additives on 
amorphous APIs and noted that effects on API mobility, as manifested by changes in Tg, could 
not fully explain changes in crystal growth rates.51 The authors hypothesised that interactions 
between the drug and additive, are very important in determining the extent of crystal growth 
inhibition.  Differences in interaction strength in amorphous blends of SDM:AA and SDM:GA 
might explain the differences in results, despite the Tg being reduced to almost the same extent.   
 
5. Conclusion 
The study has highlighted the applicability of using multiple complementary techniques in 
quantifying amorphous character in a milled drug.  We have shown that amorphisation of 
sulfadimidine could be completely eliminated following co-milling with glutaric acid while the 
API could be completely amorphised following co-milling with malic acid.  These results could 
not be anticipated based solely on the fact that both excipients are crystalline and have low Tg 
values.  The findings in this work show that excipients which have solubility parameters 
comparable to the API are more likely to exert a Tg lowering effect resulting in composite Tg 
values lower than that of the API alone, which can promote crystallisation from the amorphous 
state.   We have shown, for the SDM:GA and SDM:AA systems, that at the saturated solubility 
of excipient in amorphous API, the Tg of the co-melt quenched composites was at a minimum 
and the crystallinity of the respective co-milled systems at these concentrations of excipient were 
approaching near maximum.   Future work will focus on developing a predictive model for 
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screening crystalline excipients that can selectively mitigate amorphisation in APIs on co-
milling.  
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Figure 1.  PXRD patterns of a) SDM unprocessed; b) SDM milled; c) SDM spray dried.  
83x59mm (150 x 150 DPI)  
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Figure 2.  HyperDSC scans of a) SDM unprocessed; b) SDM spray dried; c) SDM milled.  
84x61mm (150 x 150 DPI)  
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Figure 3.  NIR spectra of a) SDM unprocessed; b) SDM spray dried; c) milled GA (see section 3.3.2.2).    
83x64mm (150 x 150 DPI)  
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Figure 4.  A) DVS sorption isotherm plots (1st cycle) for a range of known amorphous contents of SDM 
(change in mass at 20 % P/P0 highlighted); B) Calibration curve of ethanol uptake versus % amorphous 
content.  
177x47mm (150 x 150 DPI)  
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Figure 5.  PXRD patterns of unprocessed, milled and co-milled SDM:GA systems:  a) unprocessed SDM; b) 
milled SDM; c) XGA = 5; d) XGA = 10; e) XGA = 20; f) XGA = 30; g) XGA = 40; h) XGA = 50; i) milled GA.  
83x57mm (150 x 150 DPI)  
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Figure 6.  DSC scans of milled and co-milled SDM:GA systems: a) milled GA; b) XGA = 50; c) XGA = 40; d) 
XGA = 30; e) XGA = 20; f) XGA = 10; g) XGA = 5; h) milled SDM.  
82x56mm (150 x 150 DPI)  
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Figure 7.  Ethanol vapour sorption kinetics of co-milled SDM:GA composites:  A) XGA = 5; B) XGA = 10; C) 
XGA = 50.  Arrows indicate where mass loss was first observed to occur.  
82x127mm (150 x 150 DPI)  
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Figure 8.  PXRD patterns of a) unprocessed SDM; b) milled SDM c) milled AA; d) co-milled SDM 50:AA 50; 
e) milled SA; f) co-milled SDM 50:SA 50; g) milled MA; h) co-milled SDM 50:MA 50.  
84x51mm (150 x 150 DPI)  
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Figure 9.  Sorption isotherms (1st cycle) of  milled SDM and co-milled composites of SDM with excipients: 
a) SDM50:GA50; b) SDM50:SA50; c) SDM50:AA50; d) SDM milled; e) SDM50:MA50.  Error bars are 
omitted for clarity.  
84x50mm (150 x 150 DPI)  
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Figure 10.  FTIR spectra of a) SDM; b) milled SDM; c) milled GA; d) co-milled SDM 50:GA50; e) physical 
mixture SDM50:GA50; f) co-milled SDM 50:MA50; g) physical mixture SDM50:MA50; h) milled MA.  
93x66mm (150 x 150 DPI)  
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Figure 11.  PXRD patterns of a) SDM, b) milled SDM, c) co-milled milled SDM with MA, d) co-milled milled 
SDM with GA.  
84x53mm (150 x 150 DPI)  
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Figure 12.  Plot of glutaric acid mass fraction (open symbols) and adipic acid mass fraction (closed 
symbols) against heat of fusion determined by thermal analysis.  SAA and SGA refer to the saturated solubility 
of adipic acid and glutaric acid in SDM respectively.  
84x53mm (150 x 150 DPI)  
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Figure 13.  Plot of experimental Tg (closed symbols) of melt quenched samples and % crystallinity (open 
symbols) of co-milled systems as quantified by DVS as a function of A) GA mass fraction and B) AA mass 
faction. SAA and SGA are the experimental saturated solubilities of excipient in API.  
84x82mm (150 x 150 DPI)  
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